Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Archives of Neurology

• Publication date

  2012-11-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1001/ARCHNEUROL.2012.1654PMID 22925882
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diagnostic and Statistical Manual of Mental Disorders

  2013cited by this paper
• α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.

  2011cited by this paper
• The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia

  2011cited by this paper
• Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

  2011cited by this paper
• Alzheimer's disease.

  2011cited by this paper
• α-Synuclein in Parkinson disease and other neurodegenerative disorders

  2011cited by this paper
• Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

  2011cited by this paper
• CSF α-Synuclein Does Not Discriminate Dementia with Lewy Bodies from Alzheimer's Disease

  2010cited by this paper
• Biomarker discovery for Alzheimer’s disease, frontotemporal lobar degeneration, and Parkinson’s disease

  2010cited by this paper
• Differential levels of α-synuclein, β-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease

  2010cited by this paper
• Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40ox% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia

  2010cited by this paper
• Spinocerebellar ataxia type 12 identified in two Italian families may mimic sporadic ataxia

  2010cited by this paper
• Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

  2010cited by this paper
• Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

  2010cited by this paper
• Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders.

  2010cited by this paper
• Differential pattern of brain‐specific CSF proteins tau and amyloid‐beta in Parkinsonian syndromes

  2010cited by this paper
• Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease

  2010cited by this paper
• DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease.

  2010cited by this paper
• CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease.

  2009cited by this paper
• Multimodal techniques for diagnosis and prognosis of Alzheimer's disease

  2009cited by this paper
• Cerebrospinal Fluid α-Synuclein Does Not Discriminate Between Dementia Disorders

  2009cited by this paper
• Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

  2009cited by this paper
• Levels of brain related proteins in cerebrospinal fluid: an aid in the differential diagnosis of parkinsonian disorders.

  2009cited by this paper
• Neuropathological Aspects of Alzheimer Disease, Parkinson Disease and Frontotemporal Dementia

  2008cited by this paper
• Diagnostic and Statistical Manual of Mental Disorders

  2008cited by this paper
• Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration.

  2008cited by this paper
• Clinical diagnostic criteria for dementia associated with Parkinson's disease

  2007cited by this paper
• CSF biomarker profiles do not differentiate between the cerebellar and parkinsonian phenotypes of multiple system atrophy.

  2007cited by this paper
• CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease.

  2007cited by this paper
• Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study.

  2007cited by this paper
• Alzheimer's disease

  2006cited by this paper
• Beta-Amlyoid 1–42 and Tau-Protein in Cerebrospinal Fluid of Patients with Parkinson’s Disease Dementia

  2006cited by this paper
• Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease.

  2006cited by this paper
• Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

  2006cited by this paper
• OPLS discriminant analysis: combining the strengths of PLS‐DA and SIMCA classification

  2006cited by this paper
• Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease.

  2006cited by this paper
• Tau Protein, Aβ42 and S-100B Protein in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies

  2005cited by this paper
• Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium

  2005cited by this paper
• Global prevalence of dementia: a Delphi consensus study

  2005cited by this paper
• Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies.

  2005cited by this paper
• Diagnosis and management of dementia with Lewy bodies

  2005cited by this paper
• Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease

  2004cited by this paper
• Elevated neurofilament levels in neurological diseases.

  2003cited by this paper
• CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of Parkinsonian syndromes.

  2001cited by this paper
• Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects.

  2000cited by this paper
• Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects

  2000cited by this paper
• Diagnostic criteria for Parkinson disease.

  1999cited by this paper
• Consensus statement on the diagnosis of multiple system atrophy.

  1999cited by this paper
• Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple‐system atrophy compared with Parkinson's disease

  1998cited by this paper
• Consensus statement on the diagnosis of multiple system atrophy

  1998cited by this paper
• Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)

  1996cited by this paper
• Validity and Reliability of the Preliminary NINDS Neuropathologic Criteria for Progressive Supranuclear Palsy and Related Disorders

  1996cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper

• Elevated neurofilament light chain (NfL) in blood and CSF as a biomarker for Parkinson’s disease cognitive impairment: A meta-analysis

  2026cites this paper
• Combining plasma biomarkers, clinical parameters, and neuroimaging features for differential diagnosis of Parkinson’s disease and atypical parkinsonian syndromes: a multidimensional modeling approach

  2026cites this paper
• Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy.

  2026cites this paper
• Parkinson's Disease Biomarkers: Bridging the Gap Between Diagnosis and Treatment.

  2026cites this paper
• Plasma pTau217 and Neurofilament Light Chain as Differentiative Markers for Progressive Supranuclear Palsy From Parkinson Disease.

  2026cites this paper
• Biomarker Detection and Therapy of Parkinson's and Alzheimer's disease using upconversion based approach: A Comprehensive Review.

  2025cites this paper
• Biomarkers of disease progression in progressive supranuclear palsy for use in clinical trials

  2025influential citation
• Toward a biological definition of neuronal and glial synucleinopathies

  2025cites this paper
• The ketogenic diet in Parkinson’s disease: a potential therapeutic strategy

  2025cites this paper
• A novel pThr217 tau monoclonal antibody reveals neuropathological heterogeneity in tauopathies

  2025cites this paper
• Cerebrospinal fluid and blood neurofilament light chain in Parkinson's disease and atypical parkinsonian syndromes: a systematic review and Bayesian network meta-analysis

  2025influential citation
• Somatic CAG repeat expansion in blood associates with biomarkers of neurodegeneration in Huntington’s disease decades before clinical motor diagnosis

  2025cites this paper
• CNS-Tau Specific Antibodies Illuminate Disease Signatures Across Tauopathies

  2025cites this paper
• Early diagnosis of Parkinson's disease pathogenesis using biofluidic biomarkers with a focus on α-synuclein

  2025cites this paper
• Differentiating Progressive Supranuclear Palsy and Corticobasal Syndrome: Insights from Cerebrospinal Fluid Biomarkers—A Narrative Review

  2025cites this paper
• Cerebrospinal fluid biomarkers for diagnosis of Parkinson’s disease: a systematic review and network meta-analysis

  2025cites this paper
• Bioanalytical Considerations for Biomarkers of Parkinson's Disease

  2025cites this paper
• Neurofilament Light Chain in Cerebrospinal Fluid and Blood in Multiple System Atrophy: A Systematic Review and Meta-Analysis

  2025influential citation
• Fluid biomarkers in atypical Parkinsonism: current state and future perspectives

  2025cites this paper
• Modulating Cerebrospinal Fluid Composition in Neurodegenerative Processes: Modern Drug Delivery and Clearance Strategies

  2025cites this paper
• From Cell Architecture to Mitochondrial Signaling: Role of Intermediate Filaments in Health, Aging, and Disease

  2025cites this paper
• Cerebrospinal Fluid Biomarkers of NLRP3 Pathway, Immune Dysregulation, and Neurodegeneration in Parkinson's Disease: A Meta‐Analysis

  2025cites this paper
• Biomarkers for Lewy body diseases and other alpha-synucleinopathies in biofluids: current evidence and future directions

  2025cites this paper
• The 100 most influential papers on Lewy body dementias: a bibliometric analysis

  2025cites this paper
• Experimental modeling of Alzheimer's disease: Translational lessons from cross‐taxon analyses

  2025cites this paper
• Serum Oligomeric α-Synuclein and p-tau181 in Progressive Supranuclear Palsy and Parkinson’s Disease

  2024cites this paper
• The potential of phosphorylated α‐synuclein as a biomarker for the diagnosis and monitoring of multiple system atrophy

  2024cites this paper
• Alzheimer’s Disease-Related Cerebrospinal Fluid Biomarkers in Progressive Supranuclear Palsy

  2024cites this paper
• Cerebrospinal fluid protein biomarkers in Parkinson's disease.

  2024cites this paper
• Global research trends on the links between NfL and neurological disorders: A bibliometric analysis and review

  2024cites this paper
• Serum neurofilament light chain as a diagnostic and prognostic biomarker in multiple system atrophy: a prospective cohort study

  2024cites this paper
• Linking PI-2620 tau-PET, fluid biomarkers, MRI, and cognition to advance diagnostics for progressive supranuclear palsy

  2024cites this paper
• Biofluid biomarkers for Alzheimer’s disease

  2024cites this paper
• Utility of Cerebrospinal Fluid Transferrin Receptor per Ferritin Ratio in Progressive Supranuclear Palsy

  2024cites this paper
• Advances in Alzheimer's Disease Biomarkers.

  2024cites this paper
• Multiple system atrophy

  2024cites this paper
• Serum Tau Species in Progressive Supranuclear Palsy: A Pilot Study

  2024cites this paper
• Molecular Mechanisms of Neurofilament Alterations and its Application in Assessing Neurodegenerative Disorders.

  2024cites this paper
• Proximity Elongation Assay and ELISA for the Identification of Serum Diagnostic Biomarkers in Parkinson’s Disease and Progressive Supranuclear Palsy

  2024cites this paper
• Single-cell RNA sequencing reveals peripheral immunological features in Parkinson’s Disease

  2024cites this paper
• Research advancement in fluid biomarkers for Parkinson’s disease

  2024cites this paper
• Tau protein profiling in tauopathies: a human brain study

  2024cites this paper
• Diagnostic value of six plasma biomarkers in progressive supranuclear palsy, multiple system atrophy, and Parkinson's disease.

  2024cites this paper
• Neurofilaments as biomarkers in neurological disorders — towards clinical application

  2024cites this paper
• α-Synuclein in Parkinson's Disease: 12 Years Later.

  2024cites this paper
• Lysosomal and synaptic dysfunction markers in longitudinal cerebrospinal fluid of de novo Parkinson’s disease

  2024cites this paper
• Diagnostic value of isolated plasma biomarkers and its combination in neurodegenerative dementias: A multicenter cohort study.

  2024cites this paper
• Tackling the usefulness of neurofilament light chain in multiple system atrophy: diagnostic and prognostic perspectives

  2023cites this paper
• Tau-targeting therapies for Alzheimer disease: current status and future directions

  2023cites this paper
• Cerebrospinal fluid neurofilament light chain and total-tau as biomarkers of neurodegeneration in Alzheimer's disease and frontotemporal dementia.

  2023cites this paper
• Neurofilament Light Chain in Spinal Fluid and Plasma in Multiple System Atrophy – A Prospective, Longitudinal Biomarker Study

  2023cites this paper
• Neurofilament light chain in spinal fluid and plasma in multiple system atrophy: a prospective, longitudinal biomarker study

  2023cites this paper
• Blood levels of neurofilament light are associated with disease progression in a mouse model of spinocerebellar ataxia type 3

  2023cites this paper
• Multidimensional biomarkers for multiple system atrophy: an update and future directions

  2023cites this paper
• Presence of Extracellular Alpha-Synuclein Aggregates Trigger Astrocytic Degeneration Through Enhanced Membrane Rigidity and Deregulation of Store-Operated Calcium Entry (SOCE) into the Endoplasmic Reticulum

  2023cites this paper
• Head-to-head comparison of 6 plasma biomarkers in early multiple system atrophy

  2023cites this paper
• Midbrain and pons MRI shape analysis and its clinical and CSF correlates in degenerative parkinsonisms: a pilot study

  2023cites this paper
• Aβ Chronic Exposure Promotes an Activation State of Microglia through Endocannabinoid Signalling Imbalance

  2023cites this paper
• Blood neurofilament light chain levels are associated with disease progression in a transgenic SCA3 mouse model

  2023cites this paper
• Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers

  2023cites this paper
• Fluid and Biopsy Based Biomarkers in Parkinson’s Disease

  2023cites this paper
• Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy

  2023cites this paper
• Biomarkers in Parkinson’s Disease: A State of the Art Review

  2023cites this paper
• How should we be using biomarkers in trials of disease modification in Parkinson’s disease?

  2023cites this paper
• Parkinson’s disease therapy: what lies ahead?

  2023cites this paper
• Biomarkers of Neurodegenerative Diseases: Biology, Taxonomy, Clinical Relevance, and Current Research Status

  2022cites this paper
• Recent advances in establishing fluid biomarkers for the diagnosis and differentiation of alpha-synucleinopathies – a mini review

  2022cites this paper
• Neurofilament light levels predict clinical progression and death in multiple system atrophy

  2022cites this paper
• Baseline Cerebrospinal Fluid α-Synuclein in Parkinson’s Disease Is Associated with Disease Progression and Cognitive Decline

  2022cites this paper
• Biomarkers of Dementia with Lewy Bodies: Differential Diagnostic with Alzheimer’s Disease

  2022cites this paper
• Tau as a Biomarker of Neurodegeneration

  2022cites this paper
• Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease

  2022cites this paper
• Detection and assessment of alpha-synuclein in Parkinson disease.

  2022cites this paper
• Clinical Spectrum of Tauopathies

  2022cites this paper
• Multiple system atrophy

  2022cites this paper
• Beta amyloid deposition and cognitive decline in Parkinson’s disease: a study of the PPMI cohort

  2022cites this paper
• Biomarkers and diagnosis of dementia with Lewy bodies including prodromal: Practical aspects.

  2022cites this paper
• Plasma microRNAs as a Potential Biomarker for Identification of Progressive Supranuclear Palsy

  2022cites this paper
• Update on CSF Biomarkers in Parkinson’s Disease

  2022cites this paper
• Fibrinogen and Complement Factor H Are Promising CSF Protein Biomarkers for Parkinson's Disease with Cognitive Impairment─A Proteomics-ELISA-Based Study.

  2022cites this paper
• Brain volume patterns in corticobasal syndrome versus idiopathic Parkinson's disease

  2022cites this paper
• Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers

  2022cites this paper
• Comparative Analysis of Total Alpha-Synuclein (αSYN) Immunoassays Reveals That They Do Not Capture the Diversity of Modified αSYN Proteoforms

  2022cites this paper
• The genetic regulation of protein expression in cerebrospinal fluid

  2022cites this paper
• Cerebrospinal fluid neurofilament dynamic profiles predict cognitive progression in individuals with de novo Parkinson’s disease

  2022cites this paper
• A Combined Panel of Salivary Biomarkers in de novo Parkinson's Disease

  2022cites this paper
• Performance of [18F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy.

  2022cites this paper
• Parkinson's disease fluid biomarkers for differential diagnosis of atypical parkinsonian syndromes

  2022cites this paper
• Cerebrospinal Fluid Alpha-Synuclein Improves the Differentiation between Dementia with Lewy Bodies and Alzheimer’s Disease in Clinical Practice

  2022cites this paper
• Distribution of α-Synuclein Aggregation in the Peripheral Tissues

  2022cites this paper
• Alpha-synuclein: a pathological factor with Aβ and tau and biomarker in Alzheimer’s disease

  2022cites this paper
• Blood based biomarkers for movement disorders

  2022cites this paper
• Neuropathological substrates of cognition in Parkinson's disease.

  2022cites this paper
• Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration

  2022cites this paper
• Disease-Associated α-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage

  2022cites this paper
• Blood Markers of Inflammation, Neurodegeneration, and Cardiovascular Risk in Early Parkinson's Disease

  2022cites this paper
• Single domain antibodies targeting pathological tau protein: Influence of four IgG subclasses on efficacy and toxicity

  2022cites this paper
• Neurofilaments in neurologic disorders and beyond.

  2022cites this paper
• Neurofilament light as a biomarker for motor decline in Parkinson’s disease

  2022cites this paper
• Microglial Endocannabinoid Signalling in AD

  2022cites this paper